Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial

Journal:

Nature Communications

Published:

2026-01-27

DOI:

10.1038/s41467-026-68570-6

Affiliations:

15

Authors:

34

Go to article

Institutions	Authors	Share
Washington University in St. Louis (WUSTL), United States of America (USA)	25.750000 25.750000 25.750000	0.76
Roswell Park Cancer Institute (RPCI), United States of America (USA)	3.000000	0.09
Mayo Clinic, United States of America (USA)	2.000000	0.06
Massachusetts General Hospital (MGH), United States of America (USA)	1.000000	0.03
Baylor College of Medicine (BCM), United States of America (USA)	1.000000	0.03
The George Washington University (GW), United States of America (USA)	1.000000	0.03
Weill Cornell Medicine, United States of America (USA)	0.250000	0.01

Interested in Oncology and Carcinogenesis?